11 results
PRE 14A
NUVL
Nuvalent, Inc.
13 Apr 23
Preliminary proxy
4:30pm
the development of multiple molecules in breast cancer, various immune-oncology indications, acute leukemias, and chronic Graft versus Host Disease. Prior … in the U.S. Food and Drug Administration approval of COPIKTRA® for patients with follicular lymphoma, small lymphocytic lymphoma and chronic lymphocytic
DEF 14A
NUVL
Nuvalent, Inc.
29 Apr 22
Definitive proxy
4:07pm
Administration approval of COPIKTRA® for patients with follicular lymphoma, small lymphocytic lymphoma and chronic lymphocytic leukemia. Following
10-K
asxrg8r17n
29 Mar 22
Annual report
7:21am
424B4
6qtfk0t4pfejj9dct
30 Jul 21
Prospectus supplement with pricing info
4:06pm
S-1/A
kyt93pv6u 2l
22 Jul 21
IPO registration (amended)
6:07am
S-1
2oqwp0igc 4iwxz1y6
7 Jul 21
IPO registration
12:00am
DRS
kikrnvj8igbgmkzt
28 May 21
Draft registration statement
12:00am
- Prev
- 1
- Next